LENZ Therapeutics, Inc. LENZ
LENZ Therapeutics, Inc. (Nasdaq: LENZ) is an ophthalmology drug developer. Its lead program, VIZZ (aceclidine ophthalmic solution) 1.44% (LNZ100), is marketed for presbyopia.
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VIZZ (LNZ100, aceclidine 1.44%) | presbyopia | small molecule | Approved |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other approved ophthalmology companies
- Harrow, Inc. HROW
- Outlook Therapeutics, Inc. OTLK
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.